26530-93-8

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazol-6-amine,1-methyl-(9CI) is used as a building block for the synthesis of various pharmaceuticals. Its presence in the molecular structure of drugs contributes to their therapeutic effects, making it an essential component in drug development.
Used in Agrochemical Industry:
In the agrochemical sector, 1H-Benzimidazol-6-amine,1-methyl-(9CI) is utilized as a precursor in the production of agrochemicals. Its incorporation into the chemical structure of these products enhances their efficacy in agricultural applications, such as pest control and crop protection.
Used in Anticancer Research:
1H-Benzimidazol-6-amine,1-methyl-(9CI) is employed as a subject of investigation for its potential anticancer properties. Its biological activities are being studied to understand its role in inhibiting the growth and proliferation of cancer cells, offering a promising avenue for the development of novel anticancer therapeutics.
Used in Antiviral Research:
1H-Benzimidazol-6-amine,1-methyl-(9CI) is also explored for its antiviral potential. Researchers are examining its ability to interfere with viral replication and infection processes, which could lead to the creation of new antiviral agents to combat various viral diseases.

InChI:InChI=1/C8H9N3/c1-11-5-10-7-3-2-6(9)4-8(7)11/h2-5H,9H2,1H3

Upstream product

• 94-52-0 6-nitro-1H-benzo[d]imidazole 
• 74-88-4 methyl iodide 
• 95576-84-4 N₂-methyl-4-nitrobenzene-1,2-diamine 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 5381-79-3 1-methyl-6-nitro-1H-benzoimidazole 
• 5381-78-2 1-methyl-5-nitro-1H-benzo[d]imidazole 
• 94-52-0 5-nitrobenzimidazole 
• 103248-15-3 1-(N,N-dimethylaminomethyl)-6-nitrobenzimidazole 
• 51-17-2 benzoimidazole 
• 53484-16-5 6-bromo-1-methyl-1H-benzo[d]imidazole 

Downstream Products

• 744261-45-8 6-(4-fluorophenyl)-2-methyl-N-(1-methyl-1H-benzimidazol-6-yl)nicotinamide 
• 245545-79-3 3-{(Z)-1-[(1-methyl-benzimidazol-6-yl)amino]-1-phenylmethylidene}-2-indolinone 
• 135939-43-4 1-methyl-6-(p-tolylamino)benzimidazole 

Relevant academic research and scientific papers

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

QUINAZOLINE COMPOUNDS USEFUL AS M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to compounds of Formula (I): (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R7, R8, R9, R11, n and p are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modulators that are useful in the treatment of diseases in which the M1 receptor is involved, including Alzheimer's disease, schizophrenia, pain and sleep disorders. The invention also relates to pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, and to methods of using the compounds of Formula (I) in the treatment of diseases mediated by the M1 receptor.

Fusion of 2-(furan-2-yl)thiazole to 1-methyl-1H-benzimidazole

Methylation of 5(6)-nitro-1H-benzimidazole with methyl iodide in the presence of potassium hydroxide and N-methylpyrrolidin-2-one gave a mixture of isomeric 1-methyl-5-nitro- and 1-methyl-6-nitro-1H-benzimidazoles which were reduced with tin in concentrated aqueous HCl on heating. The resulting amines reacted with furan-2-carbonyl chloride in N-methylpyrrolidin-2-one to give furan-2-carboxamides which were treated with excess P2S5 in pyridine. Oxidation of isomeric furan-2-carbothioamides with K3[Fe(CN)6] in alkaline medium afforded a mixture of intramolecular cyclization products, 2-(furan-2-yl)-6-methyl-6H-imidazo[4,5-g][1,3]benzothiazole and 2-(furan-2-yl)-8-methyl-8H-imidazo[4,5-g][1,3]benzothiazole which were separated by column chromatography and identified.

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-Aβ and Aβ plaques in cells and transgenic animals.

13C and 15N NMR spectra of aminobenzimidazoles in solution and in the solid state

The 13C [hexadeutero-dimethylsulfoxide (DMSO-d6), hexamethyl-phosphoramide (HMPA)-d18 and solid-state] and 15N (solid-state) NMR spectra of six C-aminobenzimidazoles have been recorded. The tautomerism of 4(7)-aminobenzimidazoles and 5(6)- aminobenzimidazoles has been determined and compared with B3LYP/6-311++G(d,p) calculations confirming the clear predominance of the 4-amino tautomer and the slight preference for the 6-amino tautomer. GIAO-calculated absolute shieldings compare well with experimental chemical shifts. Copyright

ANTIFUNGAL AGENTS

Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

CARBOXAMIDE DERIVATIVES

Compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein P, W, X, Y, R2, R3, r and s are as defined in the specification, processes for preparing such compounds, pharmaceutical compositions comprising such compounds and their use in therapy

ALKYLATED BENZIMIDAZOLE AND BENZOTRIAZOLE DERIVATIVES OF 3-AMINO-2-PROPENOIC ACID

The alkylation of unsubstituted 3-(5-benzimidazolyl- and 5-benzotriazolyl)amino derivatives of 2-propenoic acid (I) results in the replacement of hydrogen atom at the nitrogen of YZC=CH-NH- substituent (II-IV).The model compounds with a methyl group in th

Mannich Reaction on Benzimidazoles: Part II - Synthesis and Biological Activities of Some New 1-(N-Substituted aminomethyl)-6-nitrobenzimidazoles

5(6)-Nitrobenzimidazole has been subjected to the Mannich reaction using formaldehyde and various secondary bases/aromatic primary amines.The products have been characterised as 1-aminomethyl-6-nitrobenzimidazoles (IV) by their analytical and spectral dat